CRDF has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CRDF has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Cardiff Oncology's quarterly additional paid-in capital increased from Sep. 2023 ($408.43 Mil) to Dec. 2023 ($409.34 Mil) and increased from Dec. 2023 ($409.34 Mil) to Mar. 2024 ($409.78 Mil).
Cardiff Oncology's annual additional paid-in capital increased from Dec. 2021 ($400.50 Mil) to Dec. 2022 ($404.83 Mil) and increased from Dec. 2022 ($404.83 Mil) to Dec. 2023 ($409.34 Mil).
The historical data trend for Cardiff Oncology's Additional Paid-In Capital can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cardiff Oncology Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Additional Paid-In Capital | Get a 7-Day Free Trial |
![]() |
![]() |
217.17 | 361.82 | 400.50 | 404.83 | 409.34 |
Cardiff Oncology Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Additional Paid-In Capital | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
405.90 | 407.48 | 408.43 | 409.34 | 409.78 |
Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.
Additional Paid-In Capital is calculated as
Additional Paid-In Capital | = | (Issue Price | - | Par Value) | * | Shares Outstanding (Diluted Average) |
Thank you for viewing the detailed overview of Cardiff Oncology's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.
Gary W Pace | director | C/O RESMED INC, 14040 DANIELSON STREET, POWAY CA 92064-6857 |
Fairooz Kabbinavar | officer: Chief Medical Officer | C/O TOCAGEN INC., 4242 CAMPUS POINT COURT, STE. 500, SAN DIEGO CA 92121 |
Mark Erlander | officer: Chief Scientific Officer | C/O TROVAGENE, INC., 11055 FLINTKOTE AVENUE, SUITE A, SAN DIEGO CA 92121 |
Lale White | director | 310 GODDARD, SUITE 150, IRVINE CA 92618 |
James O Armitage | director | C/O TESARO, INC., 1000 WINTER ST., SUITE 3300, WALTHAM MA 02451 |
James E. Levine | officer: Chief Financial Officer | 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142 |
Renee P Tannenbaum | director | 9220 KIRBY DRIVE, SUITE 500, HOUSTON TX 77054 |
Tod Smeal | officer: Chief Scientific Officer | 11055 FLINTKOTE AVENUE, SA DIEGO CA 92121 |
Katherine L Ruffner | officer: Chief Medical Officer | 11055 FLINTKOTE AVENUE, SAN DIEGO CA 92121 |
Mani Mohindru | director | C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, STAMFORD CT 06902 |
Rodney S Markin | director | C/O UNIVERSITY OF NEBR MEDICAL CENTER, 983135 NEBRASKA MEDICAL CENTER, OMAHA NE 68198-3135 |
Gary S Jacob | director | |
Vicki Kelemen | officer: Exec. VP and COO | 11055 FLINTKOTE AVENUE, SAN DIEGO CA 92121 |
John P Brancaccio | director | C/O TAMIR BIOTECHNOLOGY, INC., 11 DEER PARK DRIVE, SUITE 204, MONMOUTH JUNCTION NJ 08852 |
Rajeev M. Shah | 10 percent owner | 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
From GuruFocus
By PRNewswire PRNewswire • 07-05-2022
By PRNewswire • 01-17-2024
By PRNewswire • 06-21-2023
By PRNewswire PRNewswire • 05-04-2023
By PRNewswire • 11-20-2023
By PRNewswire • 08-09-2023
By PRNewswire PRNewswire • 11-03-2022
By GuruFocus Research • 11-02-2023
By PRNewswire PRNewswire • 03-28-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.